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Hodgkin disease of thymic origin
Antonio Rı´os Zambudio, MD, Juan Torres Lanzas, PhD, Pedro Jose´ Galindo Ferna´ndez, MD,
Marı´a Jose´ Roca Calvo, PhD, and Pascual Parrilla Paricio, PhD, Murcia, Spain
The thymus is a principally lymphoid organ located in theanterosuperior mediastinum and one of the main ele-ments of the immune system. Thymic disease is gener-ally uncommon, and it can be quite varied. The most
common thymic tumors are thymomas, but other types of tumors
are located in the thymus, and making a differential diagnosis is
important because treatment varies greatly from one type of dis-
ease to another.1
The fact that the thymus is a lymphoid organ makes it a site for
lymphomatous tumor, although primary lymphomas of the thymus
are uncommon.1 These lesions make up a heterogeneous group of
lymphoproliferative neoplasms, and the distinction between
Hodgkin disease and non-Hodgkin lymphoma must be made.
Thymic lymphomas must always be considered among the diag-
nostic options, because the prognosis is strongly dependent on
correct early treatment.
We report 4 cases of Hodgkin disease of thymic origin and
review the literature.
Clinical Summary
The patients were less than 40 years old (26-39 years), and 3
patients were women. The time between the onset of symptoms
and consultation was 1 to 3 months, the initial symptom being
coughing in 2 patients and dyspnea in another. The fourth patient
was asymptomatic, with only cervical adenopathies on physical
exploration (Table 1).
Simple chest radiography showed an anterosuperior mediasti-
nal tumor in all cases. Thoracic computed tomography (CT) re-
vealed a solid heterogeneous thymic tumor. One of the patients had
a pericardial effusion, and another had mediastinal adenopathies.
Nuclear magnetic resonance (NMR) imaging was done in the
patient with pericardial effusion and showed a thymic tumor
without infiltration of neighboring structures and with associated
pericardial effusion. A lymph node biopsy was obtained in the
patient with cervical adenopathies; the anatomopathologic study
was negative for lymphoma. Fine-needle aspiration of the medi-
astinal tumor was performed in 2 of the patients. In 1 patient it
suggested thymoma, and in the other it was negative for tumor
cells. The initial diagnostic suspicion was thymoma in all patients;
in 2 a differential diagnosis with lymphoma was considered, be-
cause of the presence of peripheral adenopathies in one and be-
cause of the mediastinal adenopathies found in the CT scan in the
other.
All the patients underwent a surgical procedure and all had an
intraoperative biopsy of the thymic tumor—2 because of a preop-
erative suspicion of lymphoma and the other 2 because of intra-
operative suspicion of the same. The histologic study revealed
lymphoma in 2 patients (50%) and thymoma in the other 2 (50%).
Thymectomy was performed in the 2 patients with suspected
thymoma, and only a biopsy was obtained in the 2 with lymphoma.
During the postoperative period, complications developed in the
the 2 patients having a thymectomy: a pulmonary thromboembo-
lism necessitating anticoagulation, which evolved favorably, and a
mediastinal hematoma, which required a blood transfusion (2 units
of red corpuscle concentrate).
The definitive histologic study in all cases confirmed nodular
sclerosis-type Hodgkin disease of thymic origin. Three cases were
stage I and the fourth was stage II, according to the Cotswold
classification. Treatment was with Mantle-type radiotherapy and
chemotherapy in all cases. The chemotherapy was different in each
case due to the fact that we applied the chemotherapeutic protocol
for Hodgkin disease that was most accepted at the time of diag-
nosis.
Two patients are currently asymptomatic and disease-free 20
and 16 years after diagnosis. The third patient received treatment
with 5 cycles of chemotherapy (ABVD; Adriamycin [doxorubi-
cin], bleomycin, vinblastine, and dacarbazine) and radiotherapy;
however, the persistence of a residual mediastinal mass was noted,
with uptake in gammagraphy with gallium 67 and positron emis-
sion tomography, and further cycles of chemotherapy (C-MOPP;
cyclophosphamide, mechlorethamine, Oncovin [vincristine], pro-
carbazine, and prednisone) were administered. Currently, 1 year
after diagnosis, the patient has active mediastinal disease despite
treatment. The last patient, after 2 months’ evolution, is being
treated with radiotherapy and chemotherapy, pending assessment
of the response to this therapy.
Comment
Hodgkin disease of thymic origin manifests itself in the second to
third decades of life and more frequently in men; these character-
istics differentiate it from systemic Hodgkin disease, which ap-
pears at two different ages (second to third decades and after the
fifth decade of life) and is more common in women.1-4 Clinically,
patients with Hodgkin disease of thymic origin are asymptomatic
until extrathymic disease develops, which is generally when the
diagnosis is made. As with any lymphoma, the presence of ade-
nopathies is common. This was the case in 2 of our patients: one
with cervical adenopathies and one with mediastinal adenopa-
thies.1-3 On diagnosis, a third of the patients usually have fever,
nocturnal sweating, weight loss, and other constitutional symp-
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toms,1 chest symptoms being uncommon. However, in some cases
compression or invasion of mediastinal structures may trigger
symptoms such as chest pain, coughing, or dyspnea.1
Nearly 100% of the patients have radiologic evidence of in-
trathoracic disease in the form of an anterior mediastinal narrow-
ing, as was true in our patients. CT shows a solid heterogeneous
thymic mass, with the presence of additional thoracic adenopathies
helping to suggest the correct diagnosis.1 This was noted only in
our first case. CT is very useful for assessing the invasion of
adjacent mediastinal and thoracic structures,1 although NMR has
been used in recent years since the images can better distinguish
the thymic tumor from neighboring structures. Thymic tumors
typically give off a homogeneous low-intensity signal, similar to
muscle, in sequence T1, and a mixed or a high-intensity signal,
similar to or greater than fat, in sequence T2.5
Fine-needle aspiration has been used for the differential diag-
nosis of thymic lesions, especially when thymomas are suspected.6
The cytologic state most suggestive of lymphoma is that in which
lymphoid cells predominate in the aspirate; the 2 diseases that
must be considered in the differential diagnosis are thymoma and
thymic hyperplasia.6
Despite all these diagnostic techniques it is difficult to obtain a
definitive preoperative diagnosis in most thymic lesions. There-
fore, surgeons must often resort to an open biopsy, as was true in
our cases. The approach of choice is an anterior mediastinotomy.
However, as the histologic study done for the intraoperative biopsy
TABLE 1. Our series of Hodgkin disease of thymic origin
Case 1 Case 2 Case 3 Case 4
Sex Female Female Female Male
Age 26 y 39 y 35 y 26 y
Evolution time 3 mo 2 mo 2 mo 1 mo
Onset Irritating cough Cervical adenopathy Dyspnea Irritating cough
Other symptoms Weight loss, nocturnal
sweating
No Chest tightness Fever
Simple chest
radiography
Anterosuperior mediastinal
tumor
Anterosuperior mediastinal
tumor
Anterosuperior mediastinal
tumor
Anterosuperior
mediastinal tumor
Chest CT Heterogeneous thymic tumor,
mediastinal adenopathies
Heterogeneous thymic
tumor, no adenopathies
Heterogeneous thymic
tumor, pericardial
effusion, no
adenopathies
Heterogeneous thymic
tumor, no
adenopathies
Chest NMR No No Thymic tumor not
infiltrating other
structures, pericardial
effusion, no
adenopathies
No
Lymph node
biopsy
No Yes (negative) No No
Thymic FNA No Yes (negative) No Yes (thymoma)
Diagnostic
suspicion
Lymphoma/thymoma Lymphoma/thymoma Thymoma Thymoma
Surgical approach Mediastinotomy Sternotomy Sternotomy Sternotomy
Surgical findings Thymic tumor not affecting
adjacent structures,
mediastinal adenopathies
Thymic tumor affecting
costal wall, pericardium,
and pleura
Thymic tumor infiltrating
pleura
Thymic tumor infiltrating
upper left pulmonary
lobe, mediastinal
adenopathies
Intraoperative
biopsy
Lymphoma (Hodgkin) Fibrosis—thymoma Thymoma Lymphoma
Surgical technique Biopsy Partial thymectomy Thymectomy, pericardial
window
Biopsy
Postoperative
complications
No Pulmonary
thromboembolism
Mediastinal hematoma No
Hodgkin lymphoma
type
Nodular sclerosis Nodular sclerosis Nodular sclerosis Nodular sclerosis
Cotswold staging IB IE IE IIA
Mantle-type
radiotherapy
3950 rads 3500 rads 3500 rads 3500 rads
Chemotherapy C-MOPP C-MOPP ABVD and C-MOPP ABVD
Evolution Asymptomatic (20 y) Asymptomatic (16 y) Residual disease (1 y) — (2 mo)
CT, Computed tomography; NMR, nuclear magnetic resonance; FNA, fine-needle aspiration; C-MOPP, cyclophosphamide, vincristine, procarbazine, and
prednisone; ABVD, Adriamycin (doxorubicin), bleomycin, vincristine, and dacarbazine.
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(freezing techniques) has a lower diagnostic yield than definitive
histologic tests (eg, inclusion in paraffin, immunohistochemical
techniques), the problem arises when we have a dubious diagnosis
with thymoma in patients with surgically resectable disease, in
which case there is doubt as to whether to perform thymectomy or
not. Although some authors have performed resection of the lym-
phoma in Hodgkin disease,7 most accept that biopsy is enough to
confirm the lymphoma and its variant, because treatment is che-
motherapy and radiotherapy. In our series the 2 patients who had
removal of the thymus (cases 2 and 3) had major postoperative
complications, and surgery did not improve the prognosis.
Hodgkin disease is the most common type of thymic lympho-
ma,1,4 unlike lymphomas of the rest of the organism, in which
Hodgkin disease accounts for just 20% to 25% of all cases. In most
thymic Hodgkin disease the most common histologic type is
nodular sclerosis,1,4 as the other types typically affect the lymph
nodes except the thymus.1,3 On histologic study, nodular sclerosis
Hodgkin disease is characterized by a microscopic nodularity,
composed of lymphoid cells interspersed with a marked inflam-
matory cell reaction and separated by wide fibrous bands. Identi-
fication of Reed-Sternberg cells confirms the diagnosis.1 These
lymphomas that primarily affect the thymus may be confined by
the thymic capsule or may be locally invasive.1
Because Hodgkin disease spreads through the adjacent lymph
node groups, anatomic staging is a good predictor of survival.
Classically, the Ann Arbor system has been used. This has now
been updated (Cotswold Ann Arbor modified staging system).2
Three of our patients had stage I disease and the other had stage II.
The stages in this system can be subclassified into 3 categories: A
(no generalized symptoms); B (well-defined generalized symp-
toms); or E (extralymphatic involvement).
Treatment of Hodgkin disease has varied greatly in recent
decades, and the Cotswold staging system currently enables us to
determine which patients are going to benefit from radiotherapy
and/or chemotherapy. In stages I or II with nonbulky Hodgkin
disease, radiotherapy alone is adequate. However, patients with
bulky Hodgkin disease or those who require extensive radiation of
normal tissue should be given chemotherapy followed by radio-
therapy, as occurred in our cases. In patients with stages III and IV,
treatment is chemotherapy occasionally combined with radiother-
apy.2 Most authors recommend chemotherapy followed by radio-
therapy for patients with a large mediastinal mass.2 The currently
most accepted course of chemotherapy is ABVD (Adriamycin
[doxorubicin], bleomycin, vincristine, and dacarbazine); if it is not
effective or the patient has active residual disease, it is then
complemented with C-MOPP (cyclophosphamide, vincristine,
procarbazine, prednisone), as occurred in our third case.
Sometimes a residual mass remains after treatment, and deter-
mining whether it is fibrosis or a viable tumor is difficult, espe-
cially in the first few months.5 Mediastinal ultrasound, CT, and
NMR have been used to assess these residual tumors. However,
positron emission tomography and gammagraphy with gallium 67
currently seem to be the most useful for determining whether this
residual area harbors tumor activity or merely fibrosis.8
In stages I and II the cure rates are higher than 90% with
radiotherapy alone. Stage III has a survival of 65% to 85% with
chemotherapy and radiotherapy. In stage IV these figures drop to
50% to 60%.1,2 The main factors for a poor prognosis as defined
for Hodgkin disease are large tumor size, direct invasion of the
lung or adjacent tissues, advanced stage, presence of constitutional
symptoms (category B), and age older than 50 to 60 years.2,3
Approximately 50% of the patients have recurrence of the
disease, generally in adjacent lymphatic groups and potentially
curable with aggressive chemotherapy.1,2,4 It is necessary to wait 2
decades to consider a patient totally cured with practically no
possibility of recurrence, which is why we can regard only 1 of our
4 patients as cured.
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